Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17582413 | 0.86 | GRIN2D (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21064423 | 0.75 | GRIN2D (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24411457 | 0.74 | TSHR (0.33) | — | |
| Hydrochloric Acid SCHEMBL26917230 | 0.73 | MEN1 (0.31) | — | |
| SCHEMBL24278521 | 0.71 | — | — | |
| SCHEMBL17586300 | 0.69 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL26198116 | 0.68 | — | — | |
| SCHEMBL17582314 | 0.67 | ALDH1A1 (0.34) | — | |
| SCHEMBL24497411 | 0.67 | — | — | |
| SCHEMBL21289089 | 0.67 | GRIN2D (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975035-B2 | Bicyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2019-08-01 | — | — | US | disclosed |
| US-10308609-B2 | Bicyclic compounds | Zeno Royalties & Milestones, LLC (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233377-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | GRIN2D 73/4885GRIN3B 52/4885GRIN1 91/4885 |
| US-10975035-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | GRIN2D 73/4885GRIN3B 52/4885GRIN1 91/4885 |
| US-10308609-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | GRIN2D 73/4885GRIN3B 52/4885GRIN1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.